Bizarre Patents
A method of swing on a swing is disclosed, in which a user positioned on a standard swing suspended by two chains from a substantially horizontal tree branch induces side to side motion by pulling alternately on one chain and then the other.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7691407 | Multi-component pharmaceutical dosage form A multi-component pharmaceutical dosage form comprising a plurality of drug substance—containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug substance, the sub-units being connected toge... | 04/06/2010 |
| 7462620 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis Compounds of formula (I): are inhibitors of the enzyme Lp-PLA2 and are of use in therapy, in particular for treating atherosclerosis. ... | 12/09/2008 |
| 7115616 | Pyrimidinone compounds Pyrimidinone compounds of formula (10 are inhibitors of the enzyme Lp-PLA2 and of use in therapy, in particular for treating atherosclerosis. ... | 10/03/2006 |
| 7109201 | Piperazine derivatives, their preparation and uses in therapy Compounds of formula (I) or a pharmaceutically acceptable salt thereof are disclosed: in which Ra is a group of formula (i) wherein P2 ... | 09/19/2006 |
| 7045524 | Pleuromutilin derivatives with antimicrobial activity Pleuromutilin compounds of the formula: are of use in anti-bacterial therapy. ... | 05/16/2006 |
| 6881827 | Molecular cloning of a 7TM receptor (AXOR34) and screening methods thereof AXOR34 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing AXOR34 polypeptides and polynucleotides in diagnostic assays. Further disclosed are screening assays... | 04/19/2005 |
| 6613785 | Use of glucose uptake enhancer for reducing post-ischemic injury of the heart A method for reducing post-ischaemic injury of the heart and/or improving the functional recovery of the heart following myocardial ischaemia which method comprises administration of an effective, non-toxic amount of a glucose uptake enhancer to a human o... | 09/02/2003 |
| 6521437 | Human sphingosine lyase polypeptides SPHINGLY polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilising SPHINGLY polypeptides and polynucleotides in therapy, and diagnostic assays for such.... | 02/18/2003 |
| 6515108 | Human Wnt7a polypeptides Wnt-7a polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Wnt-7a polypeptides and polynucleotides in therapy, and diagnostic assays for such.... | 02/04/2003 |
| 6432678 | Macaca cynomolgus IL 18 Macaca cynomolgus IL18 polypeptides and polynucleotides and method for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for screening for compounds which either agonize or antagonize Macaca cynomolgus IL18. S... | 08/13/2002 |
| 6361975 | Mouse aspartic secretase-2(mASP-2) mASP-2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for screening for compounds that either agonize or antagonize mASP-2. Such compounds are expected to be... | 03/26/2002 |
| 6358695 | Methods of screening for agonists and antagonists of the HNEAA81 receptor HNEAA81 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are screening methods for identifying agonists and antagonists of the interaction of the HNEAA81 receptor and its ... | 03/19/2002 |
| 6323333 | Mouse EDG1 EDG1 (mouse) polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing EDG1 (mouse) polypeptides and polynucleotides in therapy, and diagnostic assays for... | 11/27/2001 |
| 6303784 | Pharmaceutical aminophosphonic acid derivatives Aminophosphonates alpha substituted by phenol groups, of formula (I) have lipoprotein(a) lowering activity. ##STR1##... | 10/16/2001 |
| 6239267 | VANILREP1 polynucleotides and VANILREP1 polypeptides VANILREP1 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing VANILREP1 polypeptides and polynucleotides in therapy, and diagnostic assays for such.... | 05/29/2001 |
| 6238886 | Compounds SVP-1 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing SVP-1 polypeptides and polynucleotides in therapy, and diagnostic assays for such.... | 05/29/2001 |
| 6235506 | Process for the fermentative preparation of clavam derivatives whereby the levels of ammonia and urea in the fermentation medium are kept low Improved methods for the preparation of clavams by fermentation of a clavam-producing organism in a suitable medium wherein the ammonium levels are kept low so as to avoid repression of enzymes, particularly urease, are disclosed.... | 05/22/2001 |
| 6225090 | Compounds SVP4b polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing SVP4b polypeptides and polynucleotides in therapy, and diagnostic assays for such.... | 05/01/2001 |
| 6214359 | Use of a combination of amoxycillin and clavulanate in the manufacture of a medicament for the treatment drug-resistant Streptococcus pneumoniae Infections potentially caused by DRSP may be treated by a method, which comprises administering to an adult or older child patient a pharmaceutical formulation comprising from 800 to 1100 mg amoxycillin and from 100 to 150 mg clavulanate in a weight ratio... | 04/10/2001 |
| 6197495 | Methods using the staphylococcus aureus glycyl tRNA synthetase crystalline structure A novel Staphylococcus glycyl tRNA synthetase crystalline structure is identified. Also disclosed are methods of identifying inhibitors of these synthetases and/or active sites, and inhibitors identified by these methods.... | 03/06/2001 |
| 6162630 | ASP1 ASP1 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing ASP1 polypeptides and polynucleotides in the design of protocols for the treatment of Alzhe... | 12/19/2000 |
| 6110717 | Human RCE1 The hRCE1 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing hRCE1 polypeptides and polynucleotides in therapy, and diagnostic assays for such.... | 08/29/2000 |
| 6100059 | Compounds HGBAB90 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HGBAB90 polypeptides and polynucleotides in the design of protocols for the treatment of... | 08/08/2000 |
| 6100060 | Compounds Wnt-5b polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Wnt-5b polypeptides and polynucleotides in therapy, and diagnostic assays for such.... | 08/08/2000 |
| 6090583 | Compounds HTEGU07 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HTEGU07 polypeptides and polynucleotides in therapy, and diagnostic assays for such.... | 07/18/2000 |
| 6037117 | Methods using the Staphylococcus aureus glycyl tRNA synthetase crystalline structure A novel Staphylococcus glycyl tRNA synthetase crystalline structure is identified. Also disclosed are methods of identifying inhibitors of these synthetases and/or active sites, and inhibitors identified by these methods.... | 03/14/2000 |
| 6034114 | Medicament The present invention relates to the use of an angiotensin II receptor antagonist in the manufacture of a medicament for the treatment of left ventricular hypertrophy regression.... | 03/07/2000 |
| 6031115 | Process for preparing epoxides A process for preparing compounds of formula (B) wherein: one of A1 ' or A2 ' represents hydrogen and the other represents a group CF3 --Y-- wherein Y represents --CF2 --, >C.dbd.O, or --CH(OH)--, or A1 ' ... | 02/29/2000 |
| 6028091 | Medicament The present invention relates to the use of an angiotensin II receptor antagonist in the manufacture of a medicament for the treatment of diabetic nephropathy.... | 02/22/2000 |
| 6025380 | Medicament The present invention relates to the use of an angiotensin II receptor antagonist in the manufacture of a medicament for the treatment of macular degeneration.... | 02/15/2000 |
| 5998409 | Condensed indole derivatives as 5HT4 -receptor antagonists Compounds of formula (I) and pharmaceutically acceptable salts thereof: ##STR1## and their use as pharmaceuticals in the treatment of gastrointestinal disorders, cardiovascular disorders and CNS disorders.... | 12/07/1999 |
| 5985624 | Process for the fermentative preparation of clavam derivatives whereby the levels of ammonia and urea in the fermentation medium are kept low Improved methods for the preparation of clavams by fermentation of a clavam-producing organism in a suitable medium wherein the ammonium levels are kept low so as to avoid repression of enzymes, particularly urease, are disclosed.... | 11/16/1999 |
| 5889022 | Indole, indoline and quinoline derivatives with 5HT1D (anti-depressive) activity Novel indole, indoline and quinoline derivatives of formula (I) processes for their preparation, pharmaceutical compositions containing them, and their use in medicine is disclosed. A structurally distinct class of compounds have now been discovered and h... | 03/30/1999 |
| 5801170 | Heterocyclic biphenylylamides useful as 5HT1D antagonists A compound of formula (I) or a salt thereof: ##STR1## wherein P is a 5 to 7 membered heterocyclic ring selected from the group consisting of thienyl, furyl, pyrrolyl, triazolyl, diazolyl, tetrazolyl, imidazolyl, oxadiazolyl, isothiazolyl, isoxazolyl,... | 09/01/1998 |
